European Clinical Research Alliance on Infectious Diseases – PRIMary care adaptive platform trial for pandemics and Epidemics

niversity Medical Center Utrecht0 个研究点目标入组 1,700 人开始时间: 2022年11月21日最近更新: 2024年8月5日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in ECRAID-Prime, a participant must (at least) meet all the following criteria (there can be additional intervention-specific inclusion criteria):
•1. Participant is =18 years of age on the day of inclusion; if people aged <18 years are suitable for inclusion in the evaluation of an investigational product, then this will be described and justified in the relevant, approved intervention-specific appendix
•2. Presence of at least two symptoms suggestive of COVID-19 or COVID-like-illness, one respiratory (cough, sore throat, running or congested nose or sinuses, shortness of breath) and one systemic (fever, feeling feverish, sweats/chills or shivering, low energy or tiredness, headache, muscle, joint or body aches, loss of taste and/or smell)
•3. Judged by recruiting a medically qualified clinician or research nurse that the illness is due to COVID-19 or COVID-like illness
•4. Onset of symptoms less than 7 days (in case earlier treatment is required for a specific investigational product, this will be specified in the intervention-specific appendix)
•5. Willing and able to give informed consent for participation in the study
•6. Willing and able to comply with all trial procedures
•7. Any additional eligibility criteria relevant to women of child-bearing potential including current pregnancy or breastfeeding will be specified in the intervention-specific appendix

•A potential participant who meets any of the following criteria will be excluded from participation in ECRAID-Prime (there can be additional intervention-specific exclusion criteria).
•1. Requiring admission to the hospital on the day of screening, or inclusion
•2. Known allergies or hypersensitivities to any of the components used in the formulation of the investigational product, or the control product
•3. Any disease, condition, or disorder that precludes participation in the trial, in the opinion of the person checking eligibility and taking consent
•4. Any planned major surgery in the next 28 days
•5. Currently participating in a trial of an investigational product

发起方